Koa Shoji Holdings <9273> announced its consolidated financial results for the first quarter of the fiscal year ending June 2025 (July-September 24). Revenue decreased by 13.7% year-on-year to 5.027 billion yen, operating profit decreased by 6.0% to 1.125 billion yen, ordinary profit increased by 0.8% to 1.2 billion yen, and quarterly net profit attributable to the parent company shareholders increased by 4.9% to 0.794 billion yen.

The sales revenue of the pharmaceutical sales business was 2.988 billion yen (a decrease of 26.1% compared to the previous period), and the segment profit was 0.473 billion yen (a decrease of 30.9% compared to the previous period). Sales of active pharmaceutical ingredients for "sensory organ drugs" increased due to the expansion of newly launched items in recent years, while sales of active pharmaceutical ingredients for "circulatory organ drugs" and "antibiotic formulations" decreased due to inventory adjustments at existing customers mainly from the previous period, entry of competitors, and the impact of customer procurement timing.

The sales revenue of the pharmaceutical manufacturing and sales business was 2.317 billion yen (an increase of 3.9% compared to the previous period), and the segment profit was 0.62 billion yen (an increase of 18.1% compared to the previous period). Sales of pre-filled syringe formulations contracted for manufacturing have been performing well due to increased production since January 2024.

Regarding the full-year consolidated performance forecast for the fiscal year ending June 2025, revenue is expected to increase by 5.5% compared to the previous period to 23.35 billion yen, operating profit is expected to increase by 5.4% to 4.62 billion yen, ordinary profit is expected to increase by 5.3% to 4.6 billion yen, and the net income attributable to the parent company shareholders is expected to increase by 4.5% to 3.08 billion yen, maintaining the initial plan.